Brigham and Women's Hospital

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Brigham and Women's Hospital sits in the top decile of US sponsors by registered trial count (#35 of 15,742 sponsors by registered trial count).

937 total trials 145 currently recruiting 608 completed early-phase tilt top decile by trial count

Brigham and Women's Hospital: 937 sponsored US clinical trials, 145 recruiting.

Brigham and Women's Hospital sponsors 937 registered US clinical trials on ClinicalTrials.gov, 145 of them currently recruiting, and 608 completed. 124 of these trials are in Phase 3-4 (later-stage) and 197 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 2 Diabetes, with 13 trials.

Top-decile sponsor footprint

Brigham and Women's Hospital ranks in the top decile of sponsors by registered trial count (#35 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 64/100

608 of 677 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

937 total, page 10 of 19

COMPLETED Phase 2

A Novel Pharmacological Therapy for Obstructive Sleep Apnea

NCT03919955

COMPLETED

Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data

NCT05162183

COMPLETED Phase 2

Multimodality Intervention for Function and Metabolism in SCI

NCT03576001

COMPLETED NA

Skilled Nursing Facility at Home: A Pilot

NCT04048590

COMPLETED NA

Remote Physician Care for Home Hospital Patients

NCT04080570

COMPLETED NA

The Impact of a Newborn Behavioral Intervention on the Mental Health of Mothers With Late Pre-Term Infants

NCT03836430

COMPLETED

Replication of the EMPAREG Diabetes Trial in Healthcare Claims

NCT04215536

COMPLETED

Replication of the DECLARE Diabetes Trial in Healthcare Claims

NCT04215523

COMPLETED NA

The Provider Awareness and Cultural Dexterity Toolkit for Surgeons Trial

NCT03576495

COMPLETED NA

Improving Safety of Diagnosis and Therapy in the Inpatient Setting

NCT04393909

COMPLETED NA

Addressing Disparities in Lupus Care Through an Integrated Care Management Program

NCT03915652

COMPLETED Phase 3

Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)

NCT03512418

COMPLETED NA

The Impact of Music on Nociceptive Processing

NCT04087564

COMPLETED Early Phase 1

Tranexamic Acid Pharmacokinetics During Postpartum Hemorrhage

NCT03863964

COMPLETED NA

Reducing Structural Inequities in Heart Failure Management: An Approach to Improve the Quality of Heart Failure Care on the General Medicine Service: Longitudinal Equity Action Plan (LEAP)

NCT03942978

COMPLETED

Healthy Sleep for Children With Down Syndrome

NCT03922165

TERMINATED Phase 3

The Impact of Low Flow Nocturnal Oxygen Therapy on Hospital Admissions and Mortality in Patients With Heart Failure and Central Sleep Apnea

NCT03745898

COMPLETED NA

Respiratory-Gated Vagal Nerve Stimulation for Chronic Pain

NCT04053127

COMPLETED Phase 4

Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial

NCT03584854

COMPLETED NA

Computerized Decision Support to Increase Detection of Chronic Thromboembolic Pulmonary Hypertension in Patients With Prior Pulmonary Embolism

NCT03729544

TERMINATED Phase 2

24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients

NCT03702829

COMPLETED NA

Magnesium Supplementation and Blood Pressure Reduction

NCT03688503

COMPLETED NA

Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.

NCT03212794

COMPLETED NA

Efficacy of the Quell Wearable Device for Fibromyalgia

NCT03714425

COMPLETED Phase 4

Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN

NCT03683069

COMPLETED Phase 1

Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea

NCT03892772

TERMINATED Phase 2

Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes

NCT03579160

COMPLETED NA

Length of Cook Catheter Placement and Induction of Labor

NCT04233008

COMPLETED NA

Dietary Restriction in Vascular Surgery

NCT04013412

COMPLETED Phase 1

Pharmacological Intervention for Symptomatic Snoring

NCT03720353

COMPLETED

Role of Dietary Habits in Efficacy of Bariatric Surgery - Study A

NCT03470558

COMPLETED NA

Evaluation of Open-Label Conditioned Placebo Analgesia for Postoperative Opioid Reduction Following Spinal Fusion

NCT04574388

COMPLETED NA

Feasibility of a Yoga- and Mindfulness-Based Intervention for Resident Physicians

NCT03687450

COMPLETED Phase 1

Pharmacological Activation of HMN for OSA

NCT03640052

TERMINATED NA

Image-guided Lymphadanectomy in AMIGO

NCT03283423

COMPLETED Phase 4

Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use

NCT03842436

COMPLETED Phase 1

Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography

NCT03173066

COMPLETED Phase 3

Effects of Biktarvy on CFR in Stable HIV Patients

NCT03656783

COMPLETED NA

A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients

NCT03654404

COMPLETED NA

Network Modulation in Alzheimer's Disease

NCT04045990

COMPLETED

Replication of the GRADE Diabetes Trial in Healthcare Claims Data

NCT05099198

COMPLETED NA

PREventing Adverse Events Post-Discharge Through Proactive Identification, Multidisciplinary Communication, and Technology

NCT05232656

COMPLETED Phase 2

Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds

NCT03452072

TERMINATED Early Phase 1

Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis

NCT03675022

TERMINATED NA

Entrainment-Based Mechanical Ventilation

NCT03512067

COMPLETED Early Phase 1

Pro-Resolving Mediators in Acute Inflammation in Humans

NCT04308889

COMPLETED Phase 2

Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

NCT03561584

COMPLETED NA

The Impact of Music Therapy on Nociceptive Processing

NCT03692247

COMPLETED NA

VITamin D and OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers

NCT01704859

COMPLETED NA

Electronic Alerts for Stroke Prevention in Atrial Fibrillation

NCT02958943

← Previous Page 10 of 19 Next →

Phase Distribution

PhaseTrial count
Phase 1 90
Phase 2 107
Phase 3 47
Phase 4 77

What is open in the Brigham and Women's Hospital pipeline

145 recruiting of 937 indexed (15% open); 608 completed (65%).

Phase mix: 124 late (III/IV) vs 197 early (I/II) (early-phase heavy).

Top condition: Type 2 Diabetes (13 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Brigham and Women's Hospital: open-pipeline peers nationwide

Peers matched on 937 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Brigham and Women's Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 5%10%15%20% Total trials Recruiting share Brigham and Women's HospitalColumbia UniversityHoffmann-La RocheUniversity of MinnesotaUniversity of California, Los AngelesIncyte CorporationNorthwestern UniversityNationwide Children's HospitalUniversity of Michigan Rogel Cancer Center
Brigham and Women's Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Brigham and Women's Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 937 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this Brigham and Women's Hospital page

937 registered trials is a research-attention snapshot, not an endorsement of Brigham and Women's Hospital or any single study.

  • 145 of Brigham and Women's Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Type 2 Diabetes is the condition Brigham and Women's Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 2 Diabetes trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Brigham and Women's Hospital pipeline card: 937 registered trials from official public datasets.Report a data error.